



Contact:

Risa Goldman Burgess or Ted Smith
Schwartz Communications, Inc.
781-684-0770
verdezyne@schwartz-pr.com

VERDEZYNE SIGNS SECOND PROJECT WITH GENENCOR

LAGUNA HILLS, Calif.— January 14, 2009 –[Verdezyne, Inc.](http://www.verdezyne.com), a synthetic biology company focused on the industrial biotechnology markets, today announced it has signed a new project with Genencor, a division of Danisco A/S, a leading industrial biotechnology company that develops and markets innovative enzymes and bio-based products. Under the terms of the arrangement, Verdezyne will utilize its suite of technologies to generate enzyme variants.

“We are thrilled Genencor recognizes our technology as a useful, investigative tool to assist with their research initiatives,” said E. William Radany, Ph.D., President and Chief Executive Officer, Verdezyne. “We look forward to a continued, collaborative relationship with Genencor.”

Verdezyne employs its biological expertise and proprietary advanced computational algorithms to design and synthesize novel gene libraries for engineering proteins, metabolic pathways, and microorganisms to manufacture platform chemicals and biofuels.

About Genencor

Genencor, a division of Danisco A/S, is a world leader in industrial biotechnology and a pioneer in enzyme innovation and systems biology. Genencor improves process and product performance for a spectrum of industries, from biofuels and laundry detergents to animal nutrition and food. As part of a global organization, Genencor’s manufacturing and distribution network spans more than 40 countries. In collaboration with customers, technology leaders and other stakeholders, Genencor supplies competitive, biobased solutions. These innovations create value throughout the supply chain, from raw material to finished product, while building the low-carbon economy.

About Verdezyne

Founded in 2005, Verdezyne, formerly known as CODA Genomics, is a privately-held company that integrates its proprietary core technologies to direct the evolution of novel metabolic pathways for cost effective commercial production of biofuels and platform chemicals. Investors in Verdezyne include OVP Venture Partners, Monitor Ventures, Tech Coast Angels and Life Science Angels. For more information on Verdezyne, visit www.verdezyne.com.

###